Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRIGHT: BR vs R-CHOP/R-CVP in Indolent NHL/MCL
NCT00877006Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2009
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of bendamustine in Indolent Non-Hodgkin Lymphoma (INHL), mantle cell lymphoma (MCL), sponsored by Teva Pharmaceutical Industries Ltd.. Started Apr 2009; status: completed.
02
Drugs
bendamustine
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00877006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00877006.